Our Keynote breast cancer clinical trials are studying pembrolizumab to see if it may help patients with breast cancer. Pembrolizumab is an investigational immunotherapy that targets the PD-1 pathway.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
Clinical trials for breast cancer, including triple negative breast cancer (TNBC), are underway and currently enrolling patients. To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab Monotherapy for Metastatic Triple-Negative Breast Cancer||086||Breast Cancer||Phase 2||Active, not recruiting|
|Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy for Metastatic Triple Negative Breast Cancer||119||Metastatic Triple Negative Breast Cancer||Phase 3||Active, not recruiting|
|Safety and Efficacy Study of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Treatment for Participants With Triple Negative Breast Cancer||173||Triple Negative Breast Neoplasms||Phase 1||Active, not recruiting|
|Study of Pembrolizumab Plus Chemotherapy vs. Placebo Plus Chemotherapy for Previously Untreated Locally Recurrent Inoperable or Metastatic Triple Negative Breast Cancer||355||Triple Negative Breast Cancer (TNBC)||Phase 3||Active, not recruiting|
|Study of Pembrolizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer||522||Triple Negative Breast Neoplasms||Phase 3||Active, not recruiting|
|Study of Pembrolizumab Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer||756||Breast Cancer||Phase 3||Not yet recruiting|